We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+40.5%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$47M
AUM Growth
-$538M
Cap. Flow
-$549M
Cap. Flow %
-1,168.39%
Top 10 Hldgs %
25.17%
Holding
313
New
6
Increased
35
Reduced
92
Closed
155

Top Buys

Rank Stock Value
1
FLIN icon
Franklin FTSE India ETF
FLIN
+$334K
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$332K
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$224K
4
PBYI icon
Puma Biotechnology
PBYI
+$217K
5
ARRY
Array Biopharma Inc
ARRY
+$217K

Top Sells

Rank Stock Value
1
MPLX icon
MPLX
MPLX
+$60.3M
2
EQM
EQM Midstream Partners, LP
EQM
+$58.3M
3
ET icon
Energy Transfer Partners
ET
+$49.7M
4
EPD icon
Enterprise Products Partners
EPD
+$41.7M
5
MMP
Magellan Midstream Partners, L.P.
MMP
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
2 Financials 0.73%
3 Communication Services 0.52%
4 Consumer Discretionary 0.46%
5 Materials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
26
DELISTED
Epizyme, Inc
EPZM
$563K 1.2%
45,462
-5,376
-11% -$60.1K
BIIB icon
27
Biogen
BIIB
$29.9B
$562K 1.2%
2,376
+467
+24% +$147K
SRNE
28
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$512K 1.09%
107,761
-16,062
-13% -$42.1K
ASND icon
29
Ascendis Pharma A/S
ASND
$16.7B
$500K 1.06%
4,250
-539
-11% -$47.2K
VYGR icon
30
Voyager Therapeutics
VYGR
$187M
$491K 1.04%
25,651
-3,556
-12% -$46.3K
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$477K 1.01%
6,506
-778
-11% -$52.9K
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$457K 0.97%
11,716
-1,468
-11% -$42.1K
TGTX icon
33
TG Therapeutics
TGTX
$8.58B
$434K 0.92%
53,943
-7,614
-12% -$41.2K
SAGE
34
DELISTED
Sage Therapeutics
SAGE
$421K 0.9%
2,645
-303
-10% -$43.9K
BLUE
35
DELISTED
bluebird bio
BLUE
$415K 0.88%
203
-24
-11% -$42.3K
EIDX
36
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$413K 0.88%
17,604
-2,072
-11% -$33.2K
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
$411K 0.87%
30,947
-3,490
-10% -$37.1K
BHVN
38
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$381K 0.81%
7,409
-911
-11% -$39.4K
BPMC
39
DELISTED
Blueprint Medicines
BPMC
$380K 0.81%
4,741
-623
-12% -$46K
RETA
40
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$376K 0.8%
4,396
-560
-11% -$46.5K
KYNB
41
Kyntra Bio
KYNB
$28.5M
$372K 0.79%
274
-33
-11% -$44.8K
FPRX
42
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$368K 0.78%
27,492
-3,935
-13% -$44.9K
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
$367K 0.78%
26,452
-3,200
-11% -$36.6K
RARX
44
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$363K 0.77%
16,188
-1,662
-9% -$35.7K
OPTN
45
DELISTED
OptiNose
OPTN
$355K 0.76%
2,300
-255
-10% -$29.6K
TCRT icon
46
Alaunos Therapeutics
TCRT
$4.74M
$355K 0.76%
614
-72
-10% -$30.1K
STML
47
DELISTED
Stemline Therapeutics, Inc.
STML
$345K 0.73%
26,854
-2,869
-10% -$32.4K
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$336K 0.71%
6,342
-752
-11% -$37K
RGNX icon
49
Regenxbio
RGNX
$623M
$335K 0.71%
5,841
-681
-10% -$33.7K
ARWR icon
50
Arrowhead Research
ARWR
$12.1B
$333K 0.71%
18,120
-2,141
-11% -$35.3K
1
2
3 4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q1 2019 Portfolio in Review

As of Q1 2019, Virtus ETF Advisers held 313 positions worth $47M, down 92% from $585M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Virtus ETF Advisers withdrew a net $549M in Q1 2019, closing 155 positions and reducing 92 holdings. Its most notable exit was MPLX, an estimated $60.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 7.3% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Virtus ETF Advisers opened a new position in Meta Platforms (Facebook) worth $73K.

  • Virtus ETF Advisers's largest Q1 2019 buy was Meta Platforms (Facebook): 435 shares worth $73K.
  • Virtus ETF Advisers added most to Franklin FTSE India ETF in Q1 2019, an estimated $334K increase.
  • Virtus ETF Advisers's biggest Q1 2019 reduction was Marathon Petroleum, cutting an estimated $21.6M.
  • Virtus ETF Advisers fully exited MPLX in Q1 2019, selling an estimated $60.3M.
  • Virtus ETF Advisers's ten largest holdings make up 25% of its $47M portfolio in Q1 2019.
  • Virtus ETF Advisers opened 6 new positions and closed 155 in Q1 2019.
  • Virtus ETF Advisers's portfolio value fell 92% quarter-over-quarter to $47M.

Based on Virtus ETF Advisers's 13F filing for Q1 2019, filed 14 May 2019.